• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront.一名接受尼洛替尼一线治疗的慢性髓性白血病患者的斋月禁食
Case Rep Oncol. 2020 Jun 15;13(2):664-667. doi: 10.1159/000507508. eCollection 2020 May-Aug.
2
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.尼洛替尼与伊马替尼用于治疗新诊断的慢性髓性白血病。
N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.
3
Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.尼罗替尼用于治疗慢性期、加速期或急变期对伊马替尼耐药或不耐受的慢性髓性白血病：一项针对中国患者的单剂量和多剂量开放标签药代动力学研究。
Clin Ther. 2009 Jul;31(7):1568-75. doi: 10.1016/j.clinthera.2009.07.016.
4
A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience.一项关于一线尼罗替尼治疗慢性髓性白血病的回顾性队列研究：单中心经验
South Asian J Cancer. 2021 Nov 24;10(4):246-250. doi: 10.1055/s-0041-1733301. eCollection 2021 Dec.
5
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.达沙替尼和尼洛替尼治疗伊马替尼耐药或不耐受的慢性髓性白血病：系统评价和经济评估。
Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220.
6
Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.土耳其慢性期费城染色体阳性慢性髓性白血病患者一线尼罗替尼治疗：2年随访的更新结果
Hematology. 2018 Dec;23(10):771-777. doi: 10.1080/10245332.2018.1498167. Epub 2018 Jul 11.
7
[Nilotinib as a second-line treatment for chronic myeloid leukemia].尼洛替尼作为慢性髓性白血病的二线治疗药物
Gan To Kagaku Ryoho. 2011 Jun;38(6):911-5.
8
Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.达沙替尼与尼罗替尼作为卡塔尔慢性髓性白血病慢性期一线治疗的评估：一项成本效益分析
Cancer Control. 2021 Jan-Dec;28:10732748211001796. doi: 10.1177/10732748211001796.
9
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.尼洛替尼与伊马替尼治疗新诊断的费城染色体阳性慢性期慢性髓性白血病患者：3 期随机 ENESTnd 试验的 24 个月最小随访。
Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17.
10
Ophthalmologic Manifestations as Initial Presentation of Patients with Chronic Myeloid Leukemia: Report of Two Cases.慢性髓性白血病患者以眼科表现为首发症状：2例报告
Case Rep Oncol. 2020 Jan 20;13(1):7-11. doi: 10.1159/000504928. eCollection 2020 Jan-Apr.

本文引用的文献

1
Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.达沙替尼与尼罗替尼作为卡塔尔慢性髓性白血病慢性期一线治疗的评估：一项成本效益分析
Cancer Control. 2021 Jan-Dec;28:10732748211001796. doi: 10.1177/10732748211001796.
2
Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia.慢性髓性白血病中的自身免疫性溶血性贫血。
Pharmacology. 2020;105(11-12):630-638. doi: 10.1159/000507295. Epub 2020 Jun 2.
3
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.目标：对 33 个国家慢性髓性白血病的真实世界管理进行调查。
Br J Haematol. 2020 Sep;190(6):869-876. doi: 10.1111/bjh.16599. Epub 2020 Mar 30.
4
Autoimmune Hemolytic Anemia After Relapse of Chronic Myeloid Leukemia: A Case Report.慢性髓性白血病复发后自身免疫性溶血性贫血：一例报告
Clin Med Insights Blood Disord. 2019 Dec 23;12:1179545X19894578. doi: 10.1177/1179545X19894578. eCollection 2019.
5
Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?卡塔尔慢性髓性白血病患者对甲磺酸伊马替尼治疗的依从性是否与更好的临床结果相关？
Clin Med Insights Oncol. 2016 Oct 2;10:95-104. doi: 10.4137/CMO.S32822. eCollection 2016.
6
Dasatinib (Sprycel) for CML and Ph + ALL.达沙替尼（施达赛）用于治疗慢性粒细胞白血病和费城染色体阳性的急性淋巴细胞白血病。
Med Lett Drugs Ther. 2007 Jan 15;49(1252):6-7.
7
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.伊马替尼在慢性髓性白血病患者I期试验中的药代动力学和药效学
J Clin Oncol. 2004 Mar 1;22(5):935-42. doi: 10.1200/JCO.2004.03.050.

一名接受尼洛替尼一线治疗的慢性髓性白血病患者的斋月禁食

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront.

作者信息

Al-Dubai Husam N, Yassin Mohammed A, Abdulla Mohammed A, Aldapt Mahmood S, Ghassoub Rola S

机构信息

Internal Medicine Department, Hamad General Hospital, HMC, Doha, Qatar.

Department of Medical Oncology/National Centre for Cancer Care and Research, HMC, Doha, Qatar.

出版信息

Case Rep Oncol. 2020 Jun 15;13(2):664-667. doi: 10.1159/000507508. eCollection 2020 May-Aug.

DOI:10.1159/000507508
PMID:32774253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7383202/
Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm classically described as triphasic disease: chronic, accelerated, and blast crisis. There are many unmet needs and unanswered questions about CML. Intermittent fasting in patients with CML on tyrosine kinase inhibitors is among these unmet needs. Here we report the effect of intermittent fasting on response to nilotinib as upfront in a 49-year-old female Muslim who fasted during Ramadan and took her medication once instead of twice daily and remained in major molecular response.

摘要

慢性髓性白血病（CML）是一种骨髓增殖性肿瘤，传统上被描述为具有三个阶段的疾病：慢性期、加速期和急变期。关于CML存在许多未满足的需求和未解答的问题。在接受酪氨酸激酶抑制剂治疗的CML患者中进行间歇性禁食就是这些未满足的需求之一。在此，我们报告了一名49岁穆斯林女性在斋月期间禁食且将每日服药次数从两次减为一次，但仍保持主要分子学缓解的情况下，间歇性禁食对其使用尼罗替尼一线治疗反应的影响。